Akathisia and Newer Second‐Generation Antipsychotic Drugs: A Review of Current Evidence. Issue 6 (20th May 2020)

• Record Type: Journal Article
• Authors: Chow, Constance L.; Kadouh, Nour K.; Bostwick, Jolene R.; VandenBerg, Amy M.
• Is Part Of: Pharmacotherapy. Volume 40:Issue 6(2020)
• Page Start: 565
• Page End: 574
• Publication Date: 2020-05-20
• Subjects: akathisia -- antipsychotics -- bipolar disorder -- major depressive disorder -- schizophrenia; Chemotherapy -- Periodicals; Pharmacology -- Periodicals; Drug Therapy -- Periodicals; Pharmacology -- Periodicals; 615.1
• DOI: 10.1002/phar.2404
• Languages: English
• ISSNs: 0277-0008

Abstract

Abstract : Akathisia continues to present a significant challenge in clinical practice. As a class, so‐called atypical, or second‐generation, antipsychotics (SGAs) are the mainstay of treatment for schizophrenia and are commonly used to treat mood disorders. These medications have traditionally been distinguished from first‐generation antipsychotics by their lowered risk of extrapyramidal side effects (EPS) such as dystonia, dyskinesia, akathisia, and pseudoparkinsonism. However, the occurrence of EPS, particularly akathisia, has been demonstrated to some degree in all commercially available SGAs. This review examines the incidence of akathisia in nine newer SGAs in patients with schizophrenia, bipolar disorder, and major depressive disorder (MDD). We performed a search of PubMed, ClinicalTrials.gov, Cochrane Central Register, and Google Scholar, as well as manufacturer websites and product labeling for published and unpublished clinical trials, meta‐analyses, and systematic reviews. Studies evaluating adult patients with schizophrenia, bipolar disorder, or MDD were eligible for inclusion. Data on treatment‐emergent akathisia rates were gathered from each study, and potential dose‐response relationships were explored. A total of 177 studies were included in this review, comprising 58, 069 patients across 414 treatment arms. Compared with placebo with a composite 3.7% incidence of akathisia, individual SGAs produced akathisia at total composite rates ranging from 2.9–13.0% across the included studies. High doses of an SGA were generally associated with an increased risk of akathisia. Clinicians should consider the risk of akathisia when choosing a treatment option and monitor for akathisia in patients beginning therapy with an SGA or following a dose increase of the SGA.